Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tremlett, H. L
Right arrow Articles by Oger, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tremlett, H. L
Right arrow Articles by Oger, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 10, No. 3, 298-301 (2004)
DOI: 10.1191/1352458504ms1007oa
© 2004 SAGE Publications

Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes

Helen L Tremlett

University of British Columbia and Department of Medicine, Division of Neurology, Vancouver Hospital and Health Sciences Center, UBC Site, S159-2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5, tremlett{at}interchange.ubc.ca

Joel Oger

University of British Columbia and Department of Medicine, Division of Neurology, Vancouver Hospital and Health Sciences Center, UBC Site, S159-2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5

The authors report further analysis of a six-year retrospective chart review of multiple sclerosis (MS) patients prescribed interferon-beta (IFNB) in British C olumbia, C anada. A ctions and outcomes taken when 284/835 (34%) of the patients developed de novo elevated aminotransferases are presented; 239/284 (84%) of patients were continued on treatment despite these elevations; 216/246 (88%) of patients reaching grade 1 toxicity (greater than the upper limit of normal) continued IFNB treatment; of these, 167/216 (77%) returned to within normal limits. O f the 22/29 (76%) reaching grade 2 toxicity (> 2.5 times the upper limit of normal) and continuing treatment, 14/22 (64%) returned to within the normal range. O ne of the nine patients reaching grade 3 toxicity (> 5 times the upper limit of normal) was allowed continue treatment and their aminotransferase levels returned to within normal limits. However, one patient reaching grade 3 toxicity went on to develop liver failure (previously reported).

Key Words: adverse drug reaction • aminotransferase • interferon-beta • liver • multiple sclerosis • pharmacovigilance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?